Precision NanoSystems
Total Raised
$36.75MInvestors Count
16Deal Terms
2Funding, Valuation & Revenue
8 Fundings
Precision NanoSystems has raised $36.75M over 8 rounds.
Precision NanoSystems's latest funding round was a Acquired for on June 1, 2021.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
6/1/2021 | Acquired | 3 | ||||
10/23/2020 | Grant - II | |||||
8/19/2019 | Series C | |||||
12/17/2018 | Grant | |||||
5/29/2018 | Series B |
Date | 6/1/2021 | 10/23/2020 | 8/19/2019 | 12/17/2018 | 5/29/2018 |
|---|---|---|---|---|---|
Round | Acquired | Grant - II | Series C | Grant | Series B |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 3 |
Precision NanoSystems Deal Terms
2 Deal Terms
Precision NanoSystems's deal structure is available for 2 funding rounds, including their Series B from May 29, 2018.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Precision NanoSystems Investors
16 Investors
Precision NanoSystems has 16 investors. Danaher invested in Precision NanoSystems's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
6/1/2021 | 6/1/2021 | 1 Acquired | Corporation | DC | ||
10/23/2020 | 10/23/2020 | 1 Grant - II | Government | Canada | ||
9/29/2015 | 8/19/2019 | 3 Series A, Series B (2018), Series C (2019) | Venture Capital | California | ||
Government | Canada | |||||
Venture Capital | California |
First funding | 6/1/2021 | 10/23/2020 | 9/29/2015 | ||
|---|---|---|---|---|---|
Last Funding | 6/1/2021 | 10/23/2020 | 8/19/2019 | ||
Investor | |||||
Rounds | 1 Acquired | 1 Grant - II | 3 Series A, Series B (2018), Series C (2019) | ||
Board Seats | |||||
Type | Corporation | Government | Venture Capital | Government | Venture Capital |
Location | DC | Canada | California | Canada | California |
Compare Precision NanoSystems to Competitors
Lilac Pharma focuses on the development of nucleic acid drugs utilizing lipid nanoparticle technology, iLiNP. The company provides services related to nucleic acid drug development and manufacturing, as well as offering GMP-grade nucleic acid drug manufacturing equipment and cosmetic grade ingredients. Lilac Pharma serves the pharmaceutical and cosmetic industries. It is based in Sapporo, Japan.
Loading...